Half-year report · Q2
6095.TEDINET S100VQUM
Period2024-10-01 → 2025-03-31
Filed2025-05-15
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥6.3bn | 2024-10-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥14.9bn | 2023-10-01 → 2024-09-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥7.9bn | 2023-10-01 → 2024-03-31 | Cons. | Net sales |
| Operating income | ¥629m | 2024-10-01 → 2025-03-31 | Cons. | Operating income |
| Operating income | ¥836m | 2023-10-01 → 2024-03-31 | Cons. | Operating income |
| Ordinary income | ¥654m | 2024-10-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.3bn | 2023-10-01 → 2024-09-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥831m | 2023-10-01 → 2024-03-31 | Cons. | Ordinary income |
| Profit before tax | ¥654m | 2024-10-01 → 2025-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥550m | 2023-10-01 → 2024-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥427m | 2024-10-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.5bn | 2023-10-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥199m | 2023-10-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥427m | 2024-10-01 → 2025-03-31 | Cons. | Profit loss |
| Net income | ¥213m | 2023-10-01 → 2024-03-31 | Cons. | Profit loss |
| Total assets | ¥14.8bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥15.6bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥14.9bn | at 2024-03-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥5.0bn | at 2025-03-31 | Cons. | Liabilities |
| Total liabilities | ¥6.1bn | at 2024-09-30 | Cons. | Liabilities |
| Net assets / equity | ¥9.8bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥9.5bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥8.7bn | at 2024-03-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥7.2bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥7.3bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥7.2bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥7.3bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.8bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.4bn | at 2023-09-30d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥149m | 2024-10-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.9bn | 2023-10-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥807m | 2023-10-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | ¥93m | 2024-10-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥1.3bn | 2023-10-01 → 2024-09-30 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥47m | 2023-10-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥360m | 2024-10-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.3bn | 2023-10-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥378m | 2023-10-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥19.65 | 2024-10-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥68.26 | 2023-10-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥9.18 | 2023-10-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 66.1% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 60.7% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 56.5% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 43
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | revenue | 2024-10-01 → 2025-03-31 | ¥123m |
| Otherother segments | revenue external | 2024-10-01 → 2025-03-31 | ¥123m |
| Otherother segments | segment profit | 2024-10-01 → 2025-03-31 | −¥6m |
| Reconciling Itemsreconciling | revenue | 2024-10-01 → 2025-03-31 | −¥74m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-10-01 → 2025-03-31 | −¥74m |
| Reconciling Itemsreconciling | segment profit | 2024-10-01 → 2025-03-31 | −¥683m |
| jpcrp040300-q2r_E30650-000Doctor Platformreportable segment | revenue | 2024-10-01 → 2025-03-31 | ¥2.0bn |
| jpcrp040300-q2r_E30650-000Doctor Platformreportable segment | revenue external | 2024-10-01 → 2025-03-31 | ¥2.0bn |
| jpcrp040300-q2r_E30650-000Doctor Platformreportable segment | revenue intersegment | 2024-10-01 → 2025-03-31 | ¥2m |
| jpcrp040300-q2r_E30650-000Doctor Platformreportable segment | segment profit | 2024-10-01 → 2025-03-31 | ¥964m |
| jpcrp040300-q2r_E30650-000Marketing Supportreportable segment | revenue | 2024-10-01 → 2025-03-31 | ¥4.1bn |
| jpcrp040300-q2r_E30650-000Marketing Supportreportable segment | revenue external | 2024-10-01 → 2025-03-31 | ¥4.1bn |
| jpcrp040300-q2r_E30650-000Marketing Supportreportable segment | revenue intersegment | 2024-10-01 → 2025-03-31 | ¥72m |
| jpcrp040300-q2r_E30650-000Marketing Supportreportable segment | segment profit | 2024-10-01 → 2025-03-31 | ¥393m |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | revenue | 2024-10-01 → 2025-03-31 | ¥166m |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | revenue external | 2024-10-01 → 2025-03-31 | ¥166m |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | segment profit | 2024-10-01 → 2025-03-31 | −¥38m |
| —segment total | revenue | 2024-10-01 → 2025-03-31 | ¥6.3bn |
| —segment total | revenue external | 2024-10-01 → 2025-03-31 | ¥6.2bn |
| —segment total | revenue intersegment | 2024-10-01 → 2025-03-31 | ¥74m |
| —segment total | segment profit | 2024-10-01 → 2025-03-31 | ¥1.3bn |
| Otherother segments | revenue | 2023-10-01 → 2024-03-31 | ¥1.2bn |
| Otherother segments | revenue external | 2023-10-01 → 2024-03-31 | ¥1.2bn |
| Otherother segments | revenue intersegment | 2023-10-01 → 2024-03-31 | ¥419,000 |
| Otherother segments | segment profit | 2023-10-01 → 2024-03-31 | ¥159m |
| Reconciling Itemsreconciling | revenue | 2023-10-01 → 2024-03-31 | −¥23m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-10-01 → 2024-03-31 | −¥23m |
| Reconciling Itemsreconciling | segment profit | 2023-10-01 → 2024-03-31 | −¥679m |
| jpcrp040300-q2r_E30650-000Doctor Platformreportable segment | revenue | 2023-10-01 → 2024-03-31 | ¥2.0bn |
| jpcrp040300-q2r_E30650-000Doctor Platformreportable segment | revenue external | 2023-10-01 → 2024-03-31 | ¥2.0bn |
| jpcrp040300-q2r_E30650-000Doctor Platformreportable segment | revenue intersegment | 2023-10-01 → 2024-03-31 | ¥13m |
| jpcrp040300-q2r_E30650-000Doctor Platformreportable segment | segment profit | 2023-10-01 → 2024-03-31 | ¥967m |
| jpcrp040300-q2r_E30650-000Marketing Supportreportable segment | revenue | 2023-10-01 → 2024-03-31 | ¥4.4bn |
| jpcrp040300-q2r_E30650-000Marketing Supportreportable segment | revenue external | 2023-10-01 → 2024-03-31 | ¥4.4bn |
| jpcrp040300-q2r_E30650-000Marketing Supportreportable segment | revenue intersegment | 2023-10-01 → 2024-03-31 | ¥10m |
| jpcrp040300-q2r_E30650-000Marketing Supportreportable segment | segment profit | 2023-10-01 → 2024-03-31 | ¥520m |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | revenue | 2023-10-01 → 2024-03-31 | ¥234m |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | revenue external | 2023-10-01 → 2024-03-31 | ¥234m |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | segment profit | 2023-10-01 → 2024-03-31 | −¥131m |
| —segment total | revenue | 2023-10-01 → 2024-03-31 | ¥6.7bn |
| —segment total | revenue external | 2023-10-01 → 2024-03-31 | ¥6.6bn |
| —segment total | revenue intersegment | 2023-10-01 → 2024-03-31 | ¥23m |
| —segment total | segment profit | 2023-10-01 → 2024-03-31 | ¥1.4bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 515
| Item | Context | Value | Unit |
|---|---|---|---|
| Provision for point card certificates cl | Prior1YearInstant | 147888000 | JPY |
| Provision for point card certificates cl | CurrentQuarterInstant | 143261000 | JPY |
| Contract liabilities | Prior1YearInstant | 42621000 | JPY |
| Contract liabilities | CurrentQuarterInstant | 20872000 | JPY |
| Other cl | Prior1YearInstant | 284895000 | JPY |
| Other cl | CurrentQuarterInstant | 206834000 | JPY |
| Current liabilities | Prior1YearInstant | 2563680000 | JPY |
| Current liabilities | CurrentQuarterInstant | 1794072000 | JPY |
| Long term loans payable | Prior1YearInstant | 2625072000 | JPY |
| Long term loans payable | CurrentQuarterInstant | 2362584000 | JPY |
| Asset retirement obligations ncl | Prior1YearInstant | 122730000 | JPY |
| Asset retirement obligations ncl | CurrentQuarterInstant | 123628000 | JPY |
| Deferred tax liabilities | Prior1YearInstant | 727374000 | JPY |
| Deferred tax liabilities | CurrentQuarterInstant | 666373000 | JPY |
| Net defined benefit liability | Prior1YearInstant | 64531000 | JPY |
| Net defined benefit liability | CurrentQuarterInstant | 68711000 | JPY |
| Noncurrent liabilities | Prior1YearInstant | 3539708000 | JPY |
| Noncurrent liabilities | CurrentQuarterInstant | 3221297000 | JPY |
| Liabilities | Prior1YearInstant | 6103388000 | JPY |
| Liabilities | CurrentQuarterInstant | 5015370000 | JPY |
| Capital stock | Prior1YearInstant | 2256559000 | JPY |
| Capital stock | CurrentQuarterInstant | 2261965000 | JPY |
| Capital surplus | Prior1YearInstant | 2255805000 | JPY |
| Capital surplus | CurrentQuarterInstant | 2261211000 | JPY |
| Retained earnings | Prior1YearInstant | 5238820000 | JPY |
| Retained earnings | CurrentQuarterInstant | 5567812000 | JPY |
| Treasury stock | Prior1YearInstant | -300783000 | JPY |
| Treasury stock | CurrentQuarterInstant | -300783000 | JPY |
| Shareholders equity | Prior1YearInstant | 9450400000 | JPY |
| Shareholders equity | CurrentQuarterInstant | 9790204000 | JPY |
| Valuation difference on available for sale securities | Prior1YearInstant | -10951000 | JPY |
| Valuation difference on available for sale securities | CurrentQuarterInstant | -3296000 | JPY |
| Remeasurements of defined benefit plans | Prior1YearInstant | 3122000 | JPY |
| Remeasurements of defined benefit plans | CurrentQuarterInstant | 2610000 | JPY |
| Valuation and translation adjustments | Prior1YearInstant | -7828000 | JPY |
| Valuation and translation adjustments | CurrentQuarterInstant | -686000 | JPY |
| Subscription rights to shares | Prior1YearInstant | 8778000 | JPY |
| Subscription rights to shares | CurrentQuarterInstant | 8976000 | JPY |
| Net assets | Prior1YearInstant | 9451350000 | JPY |
| Net assets | CurrentQuarterInstant | 9798494000 | JPY |
| Liabilities and net assets | Prior1YearInstant | 15554738000 | JPY |
| Liabilities and net assets | CurrentQuarterInstant | 14813864000 | JPY |
| Net sales | Prior1YTDDuration | 7850221000 | JPY |
| Net sales | CurrentYTDDuration | 6312369000 | JPY |
| Cost of sales | Prior1YTDDuration | 4196668000 | JPY |
| Cost of sales | CurrentYTDDuration | 3314433000 | JPY |
| Gross profit | Prior1YTDDuration | 3653552000 | JPY |
| Gross profit | CurrentYTDDuration | 2997936000 | JPY |
| Selling general and administrative expenses | Prior1YTDDuration | 2817557000 | JPY |
| Selling general and administrative expenses | CurrentYTDDuration | 2368497000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |